Nasdaq:INM
InMed Pharmaceuticals Inc.
A biotech innovator focused on oncology drug candidates with a lean operational structure and strategic cash flow management.
Key Metrics
Investment Thesis
Bull Case
Investors may find value in InMed due to its lean balance sheet with minimal long-term liabilities and sufficient cash reserves to fund near-term operational needs without immediate dilution. The company's focus on high-need oncology segments offers the potential for significant upside if any of its drug candidates achieve regulatory approval and commercial success. Strategic partnerships could provide non-dilutive funding and accelerate market entry, creating value for shareholders in the volatile biotech sector.
Bear Case
The persistent double-digit net losses and lack of profitable operations suggest that InMed is far from reaching a sustainable revenue model or generating positive cash flow from its core products. With total assets of only $15.6M and a significant retained earnings deficit, the company lacks the financial depth to withstand prolonged clinical trial failures or market downturns. The current revenue trajectory shows minimal growth, raising concerns about the ability to generate meaningful returns before running out of cash or requiring further equity issuance.
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. is a biotechnology company specializing in the development and commercialization of novel drug candidates, primarily focused on oncology markets. The company leverages its proprietary technologies to deliver innovative therapies designed to address unmet medical needs in cancer treatment. With a streamlined balance sheet and active R&D pipeline, InMed aims to transition from clinical development to commercial success in the competitive pharmaceutical sector.
Analysis
Management Discussion
InMed reported a net loss of $8.2M for 2025, consistent with the previous year's performance, driven by high operating expenses including $9.7M in general and administrative costs and $2.9M allocated to research and development. Despite the negative cash flow from operations of $7.8M, the company successfully maintained its cash balance at $11.1M through financing activities, indicating effective liquidity management. Revenue growth remains modest at $4.9M, reflecting the early commercialization phase typical for biotech firms focused on advancing clinical candidates rather than established blockbuster drugs.
Industry Overview
The biotechnology industry is characterized by high capital intensity and long development cycles, particularly within oncology where regulatory hurdles are steep and competition is fierce. Companies in this sector often operate at a loss during clinical trial phases, relying on venture capital, public markets, or strategic partnerships to fund their pipelines until commercialization milestones are reached. Success in this industry depends heavily on scientific innovation, regulatory approval rates, and the ability to navigate complex intellectual property landscapes.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $4.1M | $4.6M | $4.9M |
| Cost of Revenue | $2.4M | $3.5M | $3.2M |
| Gross Profit | $1.4M | $1.1M | $1.7M |
| Operating Expenses | $9.8M | $9.3M | $9.7M |
| Operating Income | $-7.9M | $-8.2M | $-7.9M |
| R&D | $3.7M | $3.8M | $2.9M |
| G&A | $5.8M | $5.3M | $6.6M |
| Stock-Based Comp | $278.2K | $137.7K | $119.3K |
| D&A | $202.2K | $219.6K | $212.8K |
| Depreciation | — | $47.7K | $50.2K |
| Amortization | — | $171.9K | $162.6K |
| Other OpEx | $202.2K | $281.5K | $241.3K |
| Non-Operating Income | $13.1K | $527.9K | $-215.7K |
| Interest Income | $492.4K | $527.9K | $155.9K |
| Pre-Tax Income | $-7.9M | $-7.7M | $-8.2M |
| Income Tax | $13.1K | $7.1K | $0 |
| Continuing Ops | $-7.9M | $-7.7M | $-8.2M |
| Discontinued Ops | $15.8M | $0 | $0 |
| Net Income | $7.9M | $-7.7M | $-8.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $7.9M | $-7.7M | $-8.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $11.3M | $8.7M | $12.9M |
| Cash & Equivalents | $8.9M | $6.6M | $11.1M |
| Marketable Securities | $44.4K | $43.1K | $43.4K |
| Accounts Receivable | $260.4K | $352.8K | $465.1K |
| Inventory | $1.6M | $1.2M | $961.2K |
| Prepaid Expenses | $498.0K | $477.7K | $321.7K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $2.8M | $3.1M | $2.7M |
| PP&E (Net) | — | $1.2M | $992.2K |
| Intangibles | $1.9M | $1.8M | $1.6M |
| Other LT Assets | $828.3K | $100.0K | $100.0K |
| Total Assets | $14.1M | $11.8M | $15.6M |
| Current Liabilities | $2.0M | $2.0M | $1.8M |
| Accounts Payable | — | $41.0K | — |
| Current Leases | $375.7K | $317.8K | $435.5K |
| Other Current Liab | $1.6M | $1.4M | $1.4M |
| Long-Term Liabilities | $16.0K | $644.9K | $305.8K |
| LT Operating Leases | $16.0K | $644.9K | $305.8K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.0M | $2.6M | $2.1M |
| Shareholders' Equity | $12.1M | $9.2M | $13.4M |
| Paid-In Capital | $35.7M | — | — |
| Retained Earnings | $-101.4M | $-109.1M | $-117.2M |
| AOCI | $128.6K | $128.6K | $128.6K |
| Total L&E | $14.1M | $11.8M | $15.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $7.9M | $-7.7M | $-8.2M |
| Non-Cash Adjustments | $-13.7M | $1.0M | $1.4M |
| Working Capital Changes | $-1.4M | $-351.1K | $-1.0M |
| Cash from Operations | $-7.3M | $-7.0M | $-7.8M |
| Capital Expenditures | $160.0K | $9.3K | — |
| Cash from Investing | $-661.8K | $-9.3K | $0 |
| Cash from Financing | $10.7M | $4.7M | $12.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $2.7M | $-2.3M | $4.5M |
| Beginning Cash | $6.2M | $8.9M | $6.6M |
| Ending Cash | $8.9M | $6.6M | $11.1M |
Frequently Asked Questions
How does InMed Pharmaceuticals Inc. make money?
The company's revenue is primarily derived from product sales of its oncology-focused drug candidates, supplemented by collaboration agreements and licensing fees with external partners. Operations are concentrated in the United States with potential for international expansion as clinical trials progress.
What are the main risks for INM?
The company faces significant financial risk due to substantial net losses of $8.2M in 2025, which depletes cash reserves and requires continued investor capital injections. Regulatory uncertainty surrounding FDA approval timelines for oncology candidates poses a threat to projected revenue growth and valuation. Dependence on successful completion of clinical trials means that any failure could result in total loss of invested R&D capital. Market competition from large pharmaceutical giants developing similar cancer therapies could erode future market share and pricing power.
What is INM's competitive advantage?
InMed possesses a specialized pipeline of proprietary drug candidates targeting specific oncology indications that differentiate it from larger competitors. The company maintains a highly efficient capital structure with low debt levels, allowing for strategic flexibility during clinical development phases. Their focus on niche therapeutic areas provides targeted market access where patient needs are urgent and competition is currently limited.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.